---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-26-000010"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:23:19.827523+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mirum Pharma 2025 sales $521M (+55% YoY); guides 2026 $630-650M; multiple pipeline readouts in 2026

## Summary
- 2025 net product sales $521.3M, up from $336.4M in 2024 (+55% YoY). LIVMARLI US sales $244.7M (+69% YoY).
- 2026 guidance: global net product sales $630-650M, reflecting continued growth.
- Pipeline catalysts: Volixibat VISTAS (PSC) topline Q2 2026; Livmarli EXPAND data Q4 2026; Brelovitug HDV data H2 2026.
- Completed acquisition of Bluejay Therapeutics for brelovitug; raised $268.5M in private placements.
- Cash and investments $391.4M as of Dec 31, 2025; operating expenses $543.4M (incl. $95M non-cash).

## SEC filing metadata
- accession: 0001759425-26-000010
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000010/0001759425-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000010/mirm-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-26-000010
- JSON: https://secwatch.observer/filing/0001759425-26-000010.json
- Plain text: https://secwatch.observer/filing/0001759425-26-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.